Objective: The objective of this study was to critically appraise all the published evidences on the economic evaluation of treatment options for Parkinson’s disease.

Background: Parkinson’s disease (PD) is neurodegenerative disorders associated with substantial economic and societal burden. The increasing number of treatment options for that patients and cost effectiveness analysis studies, we need to evaluate the quality of such evidences.

Methods: A systematic search was performed in PubMed/Medline and Web of Science. To identify all English articles on economic evaluation of treatment options for Parkinson’s disease from January 01, 2012 to February 28, 2018. The Quality of Health Economic Studies (QHES) instrument was used to assess the quality of included studies.

Results: Of 927 identified articles, 16 studies were selected according to inclusion criteria. All the articles were cost-effectiveness studies that measured health outcomes using QALY units. There were four studies conducted in USA, three each in Germany and UK, two in Netherlands, and one each in Norway, Hong Kong, Italy and Japan. Markov model used across all the studies as a decision analytic model for economic evaluation. Perspective was three each for German health care provider and UK payer, US payer in two studies, societal in three studies, healthcare in two studies, and one each for Japanese health-care, National/Regional Health System (Italia/Lombardia SSN), and Medicare payer. Time horizon was lifetime in most of the studies. Discounting rate were ranges from 3 to 4%. Based on the QHES instrument 12 studies (75%) exceeded 75-point threshold for high-quality economic studies. The mean QHES scores for economic studies were 78.43±15.74.

Conclusions: Current review found the majority of cost effectiveness articles were high quality and Deep brain stimulation is the most cost effective intervention among the others. Moreover, this finding could be useful in healthcare decision making and resource allocation.

References: Chiou CF, Hay JW, Wallace JF, et al. Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care 2003;41:32–44. Ofman JJ, Sullivan SD, Neumann PJ, et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm 2003;9:53–61. Dams J, Balzer-Geldsetzer M, Siebert U, et al. Cost-effectiveness of neurostimulation in Parkinson’s disease with early motor complications. Movement Disorders 2016;31:8.

« Back to 2018 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/assessing-the-quality-of-economic-evaluation-of-treatment-options-for-parkinsons-disease-using-the-quality-of-health-economic-studies-qhes-scale/